Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Chart Of The Day: Fundamentals And Technicals Agree, Pfizer Is Heading Higher

By Pinchas CohenStock MarketsApr 13, 2021 09:24
ca.investing.com/analysis/chart-of-the-day-fundamentals-and-technicals-agree-pfizer-is-heading-higher-200460513
Chart Of The Day: Fundamentals And Technicals Agree, Pfizer Is Heading Higher
By Pinchas Cohen   |  Apr 13, 2021 09:24
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
PFE
-1.20%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-1.81%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
+0.16%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
+0.90%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

The Director General of the World Health Organization, Tedros Adhanom Ghebreyesus, warned on Monday that the pandemic is “a long way from over,” due to confusion and complacency. According to WHO's assessment, the trajectory of COVID-19 is now “growing exponentially, with over 4.4 million new virus cases last week. Naturally, that only increases global demand for the vaccine.

Among the companies whose innocultions are already available and in use, including Moderna (NASDAQ:MRNA), AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ), Pfizer's vaccine appears to be the clear leader in the race to increase market share.

That's because recent clinical trials demonstrated the Pfizer (NYSE:PFE) shot is safe and effective for the 12-15 year old cohort as well as for those 16 and older who are currently receiving it. Which positions Pfizer’s vaccine to receive FDA emergency use authorization for younger adolescents, months ahead of the competition—before schools open in the fall.

The technical perspective for Pfizer stock also broadcasts its leadership, after PFE completed back-to-back bullish patterns.

PFE Daily
PFE Daily

Pfizer extended an upside breakout of the second consecutive falling flag, bullish after sudden and sharp preceding increases. The flagpole, which was formed by the rapid almost straight up movement, caught traders unaware. In turn, they became suspicious of too-good a trade.

So they locked-in profits, then waited for further developments. Still, despite their positions unwinding, there was sufficient demand to pick up the slack. That supported the price and prevented an actual decline.

When demand absorbed all available supply within the range, buyers upped their bids to find new willing sellers at higher prices. It's a signal these buyers are serious about their positions and are willing to put up additional money to prove it. Moreover they showed they were hungry for yet more.

This spurred renewed appetite for early bulls who'd already sold off their positions, while also causing them to doubt their initial instincts to cash out. They're now covering, which is pushing the price even higher, and in the process, also finally attracting remaining, undecided investors. As such, the supply-demand scale is expected to tilt in favor of demand, which will catapult the price even higher.

Notice the symmetry of the repeated patterns. The flagpoles are nearly identical, with the first rising $1.43 and the second $1.48. Therefore, the current breakout is expected to extend for the same distance—at minimum. With a $0.55 jump from the top of the flag, there's almost another two-thirds yet to go.

This will increase if the price performs a return move, retesting the demand of the pattern. We can also see how symmetrical the pattern is, as it forms a rising channel.

After the price found resistance on Friday precisely at the 200 DMA—after piercing it on an intraday basis, but ultimately closing exactly below it—it shot through the resistance to start the new week.

The MACD’s short MA climbed back above the long MA, and the RSI is set to blow out a potential top, which tends to propel prices even higher.

Both fundamentals and technicals provide the outlook for the stock to rise. However, we expect that the previous $37.80 high on Jan. 11 will provide at least a temporary resistance. If the price makes it through, we anticipate it will keep going higher and retest the December, $43 peak.

Trading Strategies

Conservative traders should wait for the price to overcome the $38 level and find a new floor before trusting the current uptrend.

Moderate traders would be content with a 2% breakout to $37.2 and a two-day period in which the price remains above the pattern.

Aggressive traders could trade at will, provided they understand and accept the risk of a premature entry, to capture a bigger part of the move. The higher risk makes a trade plan all the more important.

Here’s an example:

Trade Sample

  • Entry: $37
  • Stop-Loss: $36
  • Risk: $1
  • Target: $43
  • Reward: $6
  • Risk:Reward Ratio: 1:6

Chart Of The Day: Fundamentals And Technicals Agree, Pfizer Is Heading Higher
 

Related Articles

Chart Of The Day: Fundamentals And Technicals Agree, Pfizer Is Heading Higher

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email